Sonnet BioTherapeutics Holdings, Inc.

SONN

US83548R3030

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 03:12:39 2024-05-15 pm EDT			5-day change	1st Jan Change
1.79 ^USD	-1.10%		+3.41%	+4.60%

Mar. 11	Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street	MT
Mar. 11	Top Premarket Gainers	MT

Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023

August 14, 2023 at 08:21 am EDT

Sonnet BioTherapeutics Holdings, Inc. reported earnings results for the third quarter and nine months ended June 30, 2023. For the third quarter, the company reported net loss was USD 3.95 million compared to USD 7.88 million a year ago. Basic loss per share from continuing operations was USD 2.86 compared to USD 40.04 a year ago.
For the nine months, net loss was USD 15.16 million compared to USD 22.29 million a year ago. Basic loss per share from continuing operations was USD 18.92 compared to USD 113.7401 a year ago.

Latest news about Sonnet BioTherapeutics Holdings, Inc.

Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street	Mar. 11	MT
Top Premarket Gainers	Mar. 11	MT
Sonnet BioTherapeutics Holdings, Inc. Announces First Phase 1b/2a Clinical Trial of SON-080	Mar. 11	CI
Chardan Cuts PT on Sonnet BioTherapeutics to $30 From $75 to Reflect Higher Projected Future Share Count, Keeps Buy Rating	Feb. 15	MT
Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 14	CI
North American Morning Briefing : Stock Futures -2-	Feb. 09	DJ
North American Morning Briefing : S&P 500 Futures Dip with Fresh Record in Sight	Dec. 20	DJ
Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Dec. 14	CI
North American Morning Briefing : Traders Await -2-	Dec. 13	DJ
Ladenburg Thalmann Starts Sonnet BioTherapeutics Holdings With Buy Rating, $7 Price Target	Nov. 27	MT
Sector Update: Health Care Stocks Retreating Late Afternoon	23-10-25	MT
Top Midday Decliners	23-10-25	MT
Top Premarket Decliners	23-10-25	MT
Sector Update: Health Care Stocks Lower in Late Afternoon Trading	23-08-31	MT
Sector Update: Health Care Stocks Lower Thursday Afternoon	23-08-31	MT
Sonnet BioTherapeutics to Implement 1-for-22 Reverse Stock Split; Shares Fall	23-08-31	MT
EF Hutton Assumes Sonnet BioTherapeutics at Buy With $6.70 Price Target	23-08-23	MT
Sector Update: Health Care Stocks Decreasing Late Afternoon	23-08-16	MT
Sector Update: Health Care Stocks Lower Wednesday Afternoon	23-08-16	MT
Sector Update: Health Care	23-08-16	MT
Top Midday Gainers	23-08-16	MT
Chardan Cuts Price Target on Sonnet BioTherapeutics to $12 From $14, Keeps Buy Rating	23-08-16	MT
Sonnet BioTherapeutics Says FDA Accepts IND for Trial of Ovarian Cancer Treatment; Shares Jump	23-08-16	MT
Sonnet Biotherapeutics Announces FDA Acceptance of the Company's IND for the SB221 Clinical Trial of SON-1010 Combined with Atezolizumab in the US	23-08-16	CI
Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-14	CI

Chart Sonnet BioTherapeutics Holdings, Inc.

Duration

Period

Chart Sonnet BioTherapeutics Holdings, Inc.

More charts

Company Profile

Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company. The Company's technology, namely Fully Human Albumin Binding (FHAB), utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The Company designed the FHAB construct to improve drug accumulation in cancer tumors, as well as to extend the duration of activity in the body. Its lead asset, SON-1010, is a fully human single-chain version of Interleukin 12 (IL-12), covalently linked to the FHAB construct, for which it is pursuing clinical development in solid tumors. Its lead clinical-stage asset, SON-080, is a fully human version of IL-6 manufactured in Chinese Hamster Ovary (CHO) cells. SON-080, for its target indications of Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN). Its pipeline also includes SON-1210, SON-1410 and SON-3015.

Sector

Pharmaceuticals

Calendar

2024-05-14 - EF Hutton Investor Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.81 USD

Average target price

12.5 USD

Spread / Average Target

+590.61%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SONNET BIOTHERAPEUTICS HOLDINGS, INC.	+4.60%	5.56M
NOVO NORDISK A/S	+31.37%	588B
JOHNSON & JOHNSON	-2.82%	364B
MERCK & CO., INC.	+20.36%	326B
ABBVIE INC.	+5.53%	285B
ASTRAZENECA PLC	+14.83%	239B
NOVARTIS AG	+9.93%	210B
ROCHE HOLDING AG	-6.95%	200B
AMGEN INC.	+11.17%	167B
PFIZER, INC.	-0.05%	161B

Other Pharmaceuticals